Clinical inertia is a global challenge affecting >50% of individuals with type 2 diabetes(T2DM). T2TA study is an initiative towards Algorithm development for T2DM treatment initiation or intensification based on FBS and PPBS outcomes to avoid clinical inertia. This study included individuals (N=200) with uncontrolled, untreated Newly diagnosed T2DM (NDDM) and Previously diagnosed T2DM (PDDM) on treatment, aged >18 years subjected to various drug combinations on Day 0. Therapy included DPP4 inhibitor (DPP4i), SGLT2 inhibitor (SGLT2i), Sulfonylurea (SU), Metformin (MET), Insulin (INS). Difference between Day 0 and Day 5 FBS, PPBS values were termed Glycemic reduction capacity (GRC) of a therapy. Therapy achieving a GRC frequently was termed the treatment of choice for initiation/intensification. GRC values were categorized into 9 glucose ranges from 1-449mg/dl. In NDDM the mean FBS, PPBS values on Day 0 were 243 ± 81 mg/dl, 350 ±106 mg/dl.On Day 5 of treatment it was 136 ± 30 mg/dl, 187 ± 69 mg/dl, with a significant reduction of mean glucose by 107 ± 82 mg/dl,164 ± 104 mg/dl. Among PDDM the mean FBS, PPBS values on Day 0 were 206 ± 62 mg/dl, 304 ± 87 mg/dl. On Day 5 of treatment it was 131 ± 35 mg/dl, 191 ± 50 mg/dl with a significant reduction of mean glucose by 76 ± 48 mg/dl, 114 ± 76 mg/dl. High GRC treatment of T2TA study can be used to develop an algorithm for treatment initiation or intensification in T2DM with significant glycemic reduction as early as Day 5 to avoid clinical inertia
S. Ramanarayanan: None.
